Last reviewed · How we verify

Adderall ® Immediate Release — Competitive Intelligence Brief

Adderall ® Immediate Release (Adderall ® Immediate Release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; CNS stimulant. Area: Neurology / Psychiatry.

marketed Sympathomimetic amine; CNS stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Adderall ® Immediate Release (Adderall ® Immediate Release) — NYU Langone Health. Adderall is a combination of amphetamine salts that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing focus and attention.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Adderall ® Immediate Release TARGET Adderall ® Immediate Release NYU Langone Health marketed Sympathomimetic amine; CNS stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET)
Propadrine PHENYLPROPANOLAMINE Alpharma Us Pharms marketed Indirectly Acting Sympathomimetic Amines Sodium-dependent noradrenaline transporter 2000-01-01
Didrex BENZPHETAMINE Pfizer marketed Sympathomimetic Amine Anorectic Alpha-1A adrenergic receptor 1960-01-01
Tenuate DIETHYLPROPION ANI Pharmaceuticals marketed Sympathomimetic Amine Anorectic Sodium-dependent dopamine transporter 1959-01-01
Aramine METARAMINOL marketed Indirectly Acting Sympathomimetic Amines Macrophage migration inhibitory factor 1954-01-01
Vialin MEPHENTERMINE Baxter marketed Indirectly Acting Sympathomimetic Amines Alpha-1A adrenergic receptor 1951-01-01
SODAS methylphenidate HCl SODAS methylphenidate HCl Massachusetts General Hospital marketed Sympathomimetic amine; CNS stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine; CNS stimulant class)

  1. Massachusetts General Hospital · 3 drugs in this class
  2. NYU Langone Health · 2 drugs in this class
  3. University of California, Los Angeles · 2 drugs in this class
  4. University of Cincinnati · 2 drugs in this class
  5. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  6. Rush University Medical Center · 1 drug in this class
  7. Seattle Children's Hospital · 1 drug in this class
  8. University of California, Davis · 1 drug in this class
  9. Rochester Center for Behavioral Medicine · 1 drug in this class
  10. BRC Operations Pty. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adderall ® Immediate Release — Competitive Intelligence Brief. https://druglandscape.com/ci/adderall-immediate-release. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: